Production of murine V-human Cr1 chimeric anti-TAG72 antibody using V region cDNA amplified by PCR

Molecular Immunology
J H XiangN Hozumi

Abstract

A mouse/human chimeric B72.3-1-3 antibody was produced by construction of a novel expression vector mpSV2neo-EP1-V-Cr1. This vector contains the neo gene as a selection marker, the murine immunoglobulin heavy chain promoter and enhancer, the murine V region cDNA containing mRNA splicing joint sequences, amplified and cloned by the PCR technique directly from the B72.3 hybridoma RNA, and the human genomic Cr1 region. The expression vector containing the murine/human chimeric immunoglobulin heavy chain gene was transfected into heavy chain loss mutant cell line, B72.3Ml. Chimeric B72.3-1-3 antibody was produced at 2 micrograms/ml and retained full binding reactivity to TAG72 compared to the murine B72.3 parental antibody. Using this method, chimeric immunoglobulin molecules can be produced rapidly in comparison with the cDNA and genomic cloning techniques.

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·F SangerA R Coulson
Dec 15, 1987·International Journal of Cancer. Journal International Du Cancer·N OhuchiJ Schlom
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R OrlandiG Winter
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·L K SunH Koprowski
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A Y LiuI Hellström
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·Z SteplewskiH Koprowski
Dec 1, 1987·Protein Engineering·N WhittleM Bodmer
Oct 1, 1987·Diseases of the Colon and Rectum·B J Sickle-SantanelloC Nieroda
Jan 1, 1987·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·D ColcherJ Schlom
Jan 15, 1987·International Journal of Cancer. Journal International Du Cancer·J M EstebanJ Schlom
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·A N HoughtonL J Old
Dec 13, 1984·Nature·G L BoulianneM J Shulman
Nov 1, 1983·The Journal of Experimental Medicine·S RudikoffM Potter
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S L MorrisonV T Oi
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·H PotterP Leder
May 15, 1983·International Journal of Cancer. Journal International Du Cancer·D StramignoniJ Schlom

❮ Previous
Next ❯

Citations

Sep 28, 2012·Molecular Biotechnology·Zahra SharifzadehSeyed Hamid Aghaee Bakhtiari
Apr 1, 1991·Current Opinion in Immunology·A C Hiatt
Jan 1, 1993·Cancer Investigation·N Hozumi, J S Sandhu
Jan 1, 1993·International Reviews of Immunology·S U ShinS L Morrison
Apr 18, 2016·Journal of Biotechnology·Laurence DelafosseYves Durocher
Feb 1, 1994·Japanese Journal of Cancer Research : Gann·T IshidaA Yachi
Dec 1, 1993·Revue française de transfusion et d'hémobiologie : bulletin de la Société nationale de transfusion sanguine·D Goossens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.